CRINETICS PHARMACEUTICALS IN's ticker is CRNX and the CUSIP is 22663K107. A total of 95 filers reported holding CRINETICS PHARMACEUTICALS IN in Q3 2021. The put-call ratio across all filers is - and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $9,293,720 | +1112.7% | 312,499 | +634.8% | 0.00% | – |
| Q2 2023 | $766,355 | +50218.8% | 42,528 | -55.1% | 0.00% | -100.0% |
| Q1 2023 | $1,523 | -85.5% | 94,807 | -83.5% | 0.00% | -83.3% |
| Q4 2022 | $10,531 | -99.8% | 575,488 | +78.9% | 0.01% | +50.0% |
| Q3 2022 | $6,319,000 | -33.5% | 321,752 | -36.8% | 0.00% | -33.3% |
| Q2 2022 | $9,499,000 | +83.2% | 509,330 | +115.7% | 0.01% | +100.0% |
| Q1 2022 | $5,184,000 | +453.8% | 236,160 | +616.5% | 0.00% | – |
| Q4 2021 | $936,000 | +267.1% | 32,959 | +172.1% | 0.00% | – |
| Q3 2021 | $255,000 | +24.4% | 12,112 | -16.7% | 0.00% | – |
| Q4 2020 | $205,000 | -89.6% | 14,538 | -87.1% | 0.00% | -100.0% |
| Q2 2020 | $1,980,000 | +337.1% | 113,034 | +526.5% | 0.00% | +200.0% |
| Q4 2019 | $453,000 | -45.4% | 18,041 | -67.3% | 0.00% | 0.0% |
| Q3 2019 | $829,000 | +310.4% | 55,149 | +520.5% | 0.00% | – |
| Q1 2019 | $202,000 | – | 8,888 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Versant Venture Management, LLC | 410,360 | $11,658,000 | 6.24% |
| 5AM Venture Management, LLC | 862,286 | $24,498,000 | 4.60% |
| Bain Capital Life Sciences Investors, LLC | 2,029,701 | $57,664,000 | 4.57% |
| Opaleye Management Inc. | 724,400 | $20,580,000 | 4.36% |
| Deep Track Capital, LP | 1,900,000 | $53,979,000 | 3.81% |
| BVF INC/IL | 3,003,879 | $85,340,000 | 3.10% |
| FRAZIER MANAGEMENT LLC | 1,384,293 | $39,328,000 | 3.03% |
| Altium Capital Management LP | 331,000 | $9,404,000 | 2.59% |
| Perceptive Advisors | 10,327,034 | $293,392,000 | 2.26% |
| MPM BioImpact LLC | 379,792 | $10,790,000 | 1.97% |